<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00086502</url>
  </required_header>
  <id_info>
    <org_study_id>0431-019</org_study_id>
    <secondary_id>Formally-A0604T2DPT</secondary_id>
    <secondary_id>2006_410</secondary_id>
    <nct_id>NCT00086502</nct_id>
  </id_info>
  <brief_title>Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of an investigational drug
      in patients with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>Change from baseline at Week 24 is defined as Week 24 minus Week 0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">353</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Sitagliptin</intervention_name>
    <description>Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Pioglitazone</intervention_name>
    <description>Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>ACTOS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin rescue for patients meeting
pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has type 2 diabetes mellitus (T2DM)

          -  Patient is 18 years of age (or older)

          -  Patient is not pregnant or breast-feeding and does not plan to become pregnant for the
             duration of the study and poststudy follow-up period

        Exclusion Criteria:

          -  Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis

          -  Patient required insulin within the prior 8 weeks

          -  Patient is on a weight loss program and is not in the maintenance phase

          -  Patient started on a weight loss medication (e.g., orlistat or sibutramine) within the
             prior 8 weeks

          -  Patient is on or likely to require treatment with treatment with immunosuppressive
             agents (e.g., cyclosporin, methotrexate)

          -  Patient has cirrhosis, active liver disease (other than fatty liver) or symptomatic
             gallbladder disease

          -  Patient has chronic myopathy, or a progressive neurological or neuromuscular disorder
             (e.g., multiple sclerosis or polymyositis)

          -  Patient has any of the following disorders within the past 6 months:

        Acute coronary syndrome (e.g., MI or unstable angina), Coronary artery intervention, Stroke
        or transient ischemic neurological disorder.

          -  Patient has new or worsening signs or symptoms of coronary heart disease within the
             past 3 months

          -  Patient has severe peripheral vascular disease

          -  Patient has congestive heart failure

          -  Patient is HIV positive

          -  Patient has a clinically important hematological disorder (e.g., aplastic anemia,
             myeloproliferative or myelodysplastic syndromes, thrombocytopenia)

          -  Patient has a history of neoplastic disease

          -  Patient has a history of alcohol or drug abuse within the past 3 years

          -  Patient has viral hepatitis (hepatitis B or C)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <reference>
    <citation>Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006 Oct;28(10):1556-68.</citation>
    <PMID>17157112</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2004</study_first_submitted>
  <study_first_submitted_qc>July 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 5, 2004</study_first_posted>
  <results_first_submitted>March 30, 2010</results_first_submitted>
  <results_first_submitted_qc>March 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 19, 2010</results_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Patient In: 15-Jul-2004.
Last Patient Last Visit: 28-Sep-2005
71 study centers worldwide</recruitment_details>
      <pre_assignment_details>Patients ≥18 years of age with type 2 diabetes mellitus and inadequate glycemic control [hemoglobin A1C
(HbA1c) ≥7.0 and ≤10.0%] who were on a stable dose of pioglitazone (≥30 mg/day) after a variable
screening period were eligible to enter the 24-week study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin 100 mg</title>
          <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label pioglitazone 15 mg oral tablets (total daily dose 30 to 45 mg/day).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>The Placebo group includes data from patients randomized to receive treatment with placebo matching sitagliptin 100 mg tablet once daily (blinded) in addition to ongoing treatment with open-label pioglitazone 15 mg oral tablets (total daily dose 30 to 45 mg/day).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Moved</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Discontinuation Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Accidentally Unblinded</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin 100 mg</title>
          <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label pioglitazone 15 mg oral tablets (total daily dose 30 to 45 mg/day).</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>The Placebo group includes data from patients randomized to receive treatment with placebo matching sitagliptin 100 mg tablet once daily (blinded) in addition to ongoing treatment with open-label pioglitazone 15 mg oral tablets (total daily dose 30 to 45 mg/day).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="175"/>
            <count group_id="B2" value="178"/>
            <count group_id="B3" value="353"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.6" spread="10.4"/>
                    <measurement group_id="B2" value="56.9" spread="11.1"/>
                    <measurement group_id="B3" value="56.2" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c (Hemoglobin A1c)</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.1" spread="0.8"/>
                    <measurement group_id="B2" value="8.0" spread="0.8"/>
                    <measurement group_id="B3" value="8.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24</title>
        <description>HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>The Full Analysis Set (FAS) included all patients with a baseline value and ≥1 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. For FAS patients with no data at Week 24, the last non-baseline observed measurement was carried forward to Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label pioglitazone 15 mg oral tablets (total daily dose 30 to 45 mg/day).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The Placebo group includes data from patients randomized to receive treatment with placebo matching sitagliptin 100 mg tablet once daily (blinded) in addition to ongoing treatment with open-label pioglitazone 15 mg oral tablets (total daily dose 30 to 45 mg/day).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24</title>
          <description>HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.</description>
          <population>The Full Analysis Set (FAS) included all patients with a baseline value and ≥1 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. For FAS patients with no data at Week 24, the last non-baseline observed measurement was carried forward to Week 24.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" lower_limit="-0.98" upper_limit="-0.72"/>
                    <measurement group_id="O2" value="-0.15" lower_limit="-0.28" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Model terms: treatment; baseline; prior antihyperglycemic
agent (AHA) therapy [not on AHA, monotherapy with oral AHA, peroxisome proliferator-activated receptor (PPAR)-based combination therapy]</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.70</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>-0.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24</title>
        <description>Change from baseline at Week 24 is defined as Week 24 minus Week 0.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>The Full Analysis Set (FAS) included all patients with a baseline value and ≥1 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. For FAS patients with no data at Week 24, the last non-baseline observed measurement was carried forward to Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label pioglitazone 15 mg oral tablets (total daily dose 30 to 45 mg/day).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The Placebo group includes data from patients randomized to receive treatment with placebo matching sitagliptin 100 mg tablet once daily (blinded) in addition to ongoing treatment with open-label pioglitazone 15 mg oral tablets (total daily dose 30 to 45 mg/day).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24</title>
          <description>Change from baseline at Week 24 is defined as Week 24 minus Week 0.</description>
          <population>The Full Analysis Set (FAS) included all patients with a baseline value and ≥1 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. For FAS patients with no data at Week 24, the last non-baseline observed measurement was carried forward to Week 24.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.7" lower_limit="-22.4" upper_limit="-11.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-4.3" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Model terms: treatment; baseline; prior antihyperglycemic agent (AHA) therapy [not on AHA, monotherapy with oral AHA, peroxisome proliferator-activated receptor (PPAR)-based combination therapy]</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-17.7</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>30.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-24.3</ci_lower_limit>
            <ci_upper_limit>-11.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 0 through Week 24.</time_frame>
      <desc>Other (not including serious) adverse experience results represent those events included in the primary
safety analysis for this study (i.e., events that occurred prior to the initiation of glycemic rescue therapy).</desc>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin 100 mg</title>
          <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label pioglitazone 15 mg oral tablets (total daily dose 30 to 45 mg/day).</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>The Placebo group includes data from patients randomized to receive treatment with placebo matching sitagliptin 100 mg tablet once daily (blinded) in addition to ongoing treatment with open-label pioglitazone 15 mg oral tablets (total daily dose 30 to 45 mg/day).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Any Gastrointestinal Disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Ileitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any General Disorders And Administration Site Conditions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Any Hepatobiliary Disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Any Immune System Disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Any Injury, Poisoning And Procedural Complications</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Any Musculoskeletal And Connective Tissue Disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Any Neoplasms Benign, Malignant And Unspecified (Incl Cysts And Polyps)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Non-Small Cell Lung Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Any Nervous System Disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Any Pregnancy, Puerperium And Perinatal Conditions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Any Psychiatric Disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Any Skin And Subcutaneous Tissue Disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Angioneurotic Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Any Vascular Disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Atherosclerosis Obliterans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Any Infections And Infestations</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Any Nervous System Disorders</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

